Aaron Cooper
Vice President, Early Discovery Arsenal Biosciences, Inc.
Aaron Cooper is Vice President, Early Discovery at Arsenal Biosciences, where he leads early discovery programs advancing next-generation cell therapies for cancer. He is a group partner and leader with broad expertise in synthetic biology, gene editing, immunology, large-scale retroviral vector production, and NGS and computational biology methods for advancing drug development, supporting cross-functional teams to achieve product development goals. His work includes focused product development of cell therapies for cancer and development of discovery technologies built on cell barcoding and artificial intelligence. Aaron holds a Doctor of Philosophy (Ph.D.), Molecular Biology from UCLA and a Bachelor of Arts (B.A.), Biology from Pomona College.
Seminars
- Strengthening CAR-T selectivity with logic gating to safely target solid tumors
- Enhancing CAR-T potency with modular engineering to endure the tumor microenvironment
- Enabling translational readouts to validate cell therapy module function in the clinic
